RESEARCH ARTICLE

Time to HAART Initiation after Diagnosis and Treatment of Opportunistic Infections in Patients with AIDS in Latin America

Brenda Crabtree-Ramírez1*, Yanink Caro-Vega1, Bryan E. Shepherd2, Beatriz Grinsztejn3, Marcelo Wolff4, Claudia P. Cortes4, Denis Padgett5, Gabriela Carriquiry6, Valeria Fink7, Karu Jayathilaka8, Anna K. Person8, Catherine McGowan8, Juan Sierra-Madero1,
Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet), of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Program

1 Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Infectious Diseases Department, Mexico City, Mexico, 2 Vanderbilt University, Department of Biostatistics, Nashville, TN, United States of America, 3 Instituto Nacional de Infectología Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil, 4 Universidad de Chile- Fundación Arriarán, Santiago, Chile, 5 Instituto Hondureño de Seguro Social and Hospital Escuela Universitario, Tegucigalpa, Honduras, 6 Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru, 7 Fundación Huésped, Investigaciones Clínicas, Buenos Aires, Argentina, 8 Vanderbilt University, Department of Medicine, Nashville, TN, United States of America

* brendcrabtree@hotmail.com

Abstract

Background
Since 2009, earlier initiation of highly active antiretroviral therapy (HAART) after an opportunistic infection (OI) has been recommended based on lower risks of death and AIDS-related progression found in clinical trials. Delay in HAART initiation after OIs may be an important barrier for successful outcomes in patients with advanced disease. Timing of HAART initiation after an OI in “real life” settings in Latin America has not been evaluated.

Methods
Patients in the Caribbean, Central and South America network for HIV Epidemiology (CCASAnet) ≥18 years of age at enrolment, from 2001–2012 who had an OI before HAART initiation were included. Patients were divided in an early HAART (EH) group (those initiating within 4 weeks of an OI) and a delayed HAART (DH) group (those initiating more than 4 weeks after an OI). All patients with an AIDS-defining OI were included. In patients with more than one OI the first event reported was considered. Calendar trends in the proportion of patients in the EH group (before and after 2009) were estimated by site and for the whole cohort. Factors associated with EH were estimated using multivariable logistic regression models.

Results
A total of 1457 patients had an OI before HAART initiation and were included in the analysis: 213 from Argentina, 686 from Brazil, 283 from Chile, 119 from Honduras and 156 from...
signing of a Data Use Agreement before HIV clinical data can be released. To request data, readers may contact Principal Investigator Dr. Catherine McGowan (c.mcgowan@vanderbilt.edu) and the data manager, Karu Jayathilake (karu.jayathilake@vanderbilt.edu). Statistical scripts are deposited into Figshare at the following URLs: https://figshare.com/articles/HAART_after_OI_code/3365227 and https://figshare.com/articles/HAART_after_OI_report_txt/3365158.

Funding: This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute (NCI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) as part of the International epidemiologic Databases to Evaluate AIDS (IeDEA): U01 AI069923.

Competing Interests: The authors have declared that no competing interests exist.

Discussion
The time from diagnosis of an OI to HAART initiation has decreased in Latin America coinciding with the publication of evidence of its benefit. We found important heterogeneity between sites which may reflect differences in clinical practices, local guidelines, and access to HAART. The impact of the timing of HAART initiation after OI on patient survival in this “real life” context needs further evaluation.

Introduction
Although universal access to antiretroviral therapy in Latin America has been accomplished in most countries of the region, a large proportion of HIV-infected individuals still present late for care and therefore initiate HAART with low CD4 counts and/or with an AIDS-defining event (ADE) [1]. This population is more likely to progress to advanced stages of clinical AIDS, have poor immunologic response, and die [2–5]. The optimal timing of initiation of HAART in patients presenting with an ADE was debated in the early HAART era because of concerns of increased adverse outcomes such as overlapping toxicities of both treatments and risk of immune reconstitution inflammatory syndrome (IRIS) [6]. In 2009, the AIDS Clinical Trials Group (ACTG protocol 5164) reported that starting antiretroviral therapy within the first 30 days after a diagnosis of non-tuberculosis opportunistic infections (OI) was associated with a lower rate of AIDS progression and death, compared to delaying initiation of HAART, without an increase in adverse outcomes [7]. Other observational studies performed after ACTG 5164 support the early initiation of HAART after an ADE [8]. Moreover, recent clinical trials demonstrated a survival benefit in patients with HIV and tuberculosis with CD4 counts <50 cells/mm³ who initiate HAART early [9–12]. Furthermore, in a mathematical model of HIV disease to project the short- and long-term survival and costs of treating HIV-infected patients who present to care with acute OIs in the United States, early HAART initiation was suggested to be cost-effective [13]. Therefore most international guidelines currently recommend HAART initiation as early as possible after an ADE [14]. However, there is a lack of information of how in “real life” settings these recommendations are followed. In order to evaluate the implementation of this practice in individuals presenting with OIs, we aimed to evaluate the temporal trends of the time from a first diagnosis of OI to the time of starting HAART in HIV-positive treatment-naïve adults from the Caribbean, Central, and South America Network for HIV Epidemiology (CCASAnet) cohort.

Methods
Cohort
The Caribbean, Central, and South America Network (http://ccasanet.vanderbilt.edu/) has been described elsewhere [15]. CCASAnet is a consortium of HIV clinics from 7 countries (Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru) and is a member cohort of the...
International Epidemiologic Databases to Evaluate AIDS (IeDEA; www.iedea.org). Five CCA-SAnet sites who routinely collect clinical endpoints, contributed to this study: Fundación Huesped, Buenos Aires, Argentina (FH-Argentina); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil (FC- Brazil); Fundación Arriarán, Santiago, Chile (FA-Chile); Instituto Hondureño de Seguridad Social and Hospital Escuela, Tegucigalpa, Honduras (IHSS/HE-Honduras) and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico (INCMNSZ-Mexico).

Study population
HIV-infected individuals were included if they were at least 18 years of age at enrolment from January 2001 to January 2012, and had an AIDS-defining opportunistic infection according to either WHO or CDC case definitions [16–17] before HAART initiation and no more than 30 days before entrance to care. Patients were divided into two groups based on previous studies evaluating the timing of HAART introduction [9–11]: those who initiated HAART within 4 weeks after the OI diagnosis (early HAART, EH) and those who initiated later than 4 weeks (delayed HAART, DH). All AIDS-related opportunistic infections were included. In patients with more than one opportunistic infection, the date of the first reported event was used.

Statistical analysis
The probability of starting HAART over time for OIs occurring before and after January 1, 2009 was estimated using Kaplan-Meier curves. Additional analyses considered OIs due to tuberculosis (TB) or cryptococcal meningitis (CM). Factors associated with early HAART initiation (starting within 4 weeks after the diagnosis of OI) were estimated by logistic regression. Trends in the median time since the OI to HAART initiation according to year of OI were estimated with median regression controlling for gender, age, route of HIV transmission, site, CD4 count at enrolment, calendar year of OI, and whether the OI was tuberculosis or not. Continuous variables such as age, CD4 count at enrolment and calendar year were included in the regression models using restricted cubic splines. Statistical analyses were performed using R version 2.11.1 and analysis scripts are available at http://biostat.mc.vanderbilt.edu/ArchivedAnalyses.

Ethics statement
Institutional ethics review boards from all sites and the CCASAnet Data Coordinating Center at Vanderbilt University, Nashville, TN, U.S.A. approved the project, waiving the requirement for individual patient informed consent.

Results
Study population
From a total of 12248 eligible patients, 1457 had an OI after enrolment but prior to HAART initiation, all of whom were included in analyses (Fig 1). FH-Argentina contributed 213 patients, FC-Brazil 686, FA-Chile 283, IHSS/HE-Honduras 119, and INCMNSZ-Mexico 156. Baseline characteristics of the study population are shown in Table 1. The median age at OI in the combined group was 36 years (interquartile range: 30–43); 77% were male and heterosexual transmission was the probable route of transmission for 45% of patients, although with varying proportions across sites. The median CD4 count at enrolment was 68 cells/mm³ with a high proportion missing CD4 count at enrolment, ranging from 26% to 62%. The different OIs and their frequencies by site are listed in Table 2. Tuberculosis was the most frequent OI, representing 32% of all OI cases (n = 453) followed by P. jiroveci pneumonia (n = 350), esophageal
candidiasis (n = 237), and toxoplasmosis (n = 133). There were 51 cases of cryptococcal meningitis.

**Timing of HAART initiation after an OI and temporal trends**

The median time to HAART initiation after an OI was 5.1 weeks, and varied significantly between sites (from 2.6 weeks in IHSS/HE-Honduras to 7.4 weeks in FH-Argentina). Overall, 40% of patients started HAART within 4 weeks of their OI diagnosis; the percentage of individuals in the early HAART group also varied substantially between sites (from 28% in FH-Argentina to 68% in IHSS/HE-Honduras). The median time since the occurrence of an OI to HAART initiation was 5.7 weeks before 2009, and decreased to 4.3 weeks after that year (p<0.01). The probability of starting HAART over time after diagnosis with any OI, and after a diagnosis with TB or cryptococcal meningitis, is shown in Fig 2. In all cases, except for cryptococcal meningitis, the time to starting HAART was statistically shorter after 2009.

Fig 3 shows trends over calendar year in the time to HAART initiation after an OI. Panel A shows the median time to HAART initiation per year. Panel B shows the median time to HAART initiation per year after controlling for study site, age, gender, route of HIV transmission, and CD4 count at enrolment to care, and TB diagnosis. Panel C shows the estimated
### Table 1. Baseline patient characteristics according to site, and combined.

| Site                  | FH-Argentina (n = 213) | FC-Brazil (n = 686) | FA-Chile (n = 283) | IHSS/HE-Honduras (n = 119) | INCMSNZ-México (n = 156) | Combined (n = 1457) |
|-----------------------|-----------------------|--------------------|-------------------|---------------------------|--------------------------|-------------------|
| **Age (years)**       |                       |                    |                   |                           |                          |                   |
|                       | 34 (30–40)            | 37 (30–44)         | 36 (31–44)        | 36 (30–42)                | 35 (28–42)               | 36 (30–43)        |
| **Male**              | 165 (77.45%)          | 509 (74.2%)        | 257 (90.8%)       | 64 (53.7%)                | 138 (88.46%)             | 1133 (77.76%)    |
| **CD4 at enrolment**  |                       |                    |                   |                           |                          |                   |
| (cells/mm³)           | 62 (21–122)           | 87 (35–252)        | 55 (20–173)       | 80 (46–147)               | 46 (17–106)              | 68 (25–197)       |
| **Missing, n (%)**    | 132 (61.9%)           | 351 (51.17%)       | 123 (43.46%)      | 39 (32.77%)               | 40 (25.64%)              | 643 (45.5%)       |
| **TB cases**          | 27 (12.6%)            | 340 (49.56%)       | 21 (7.42%)        | 26 (21.8%)                | 40 (25.6%)               | 454 (31.16%)      |
| **Cryptoccocal meningitis cases** | 16 (7.51%) | 14 (2.04%) | 11 (3.8%) | 8 (6.7%) | 2 (1.26%) | 51 (3.5%) |
| **Route of Transmission** |                       |                    |                   |                           |                          |                   |
| Heterosexual          | 98 (46.01%)           | 345 (50.29%)       | 92 (32.51%)       | 74 (62.18%)               | 53 (33.97%)              | 662 (45.44%)      |
| MSM                   | 73 (34.27%)           | 216 (31.49%)       | 188 (66.43%)      | 4 (3.36%)                 | 94 (60.26%)              | 575 (39.46%)      |
| Other                 | 35 (16.43%)           | 15 (2.19%)         | 2 (0.71%)         | 0 (0%)                    | 5 (3.21%)                | 57 (3.91%)        |
| Unknown               | 7 (3.29%)             | 110 (16.03%)       | 1 (<1%)           | 41 (34.45%)               | 4 (2.56%)                | 163 (11.19%)      |
| **HAART regimen, n (%)** |                       |                    |                   |                           |                          |                   |
| NNRTI                 | 113 (53.05%)          | 524 (76.38%)       | 249 (87.99%)      | 116 (97.48%)              | 120 (76.9%)              | 1122 (77.01%)     |
| PI                    | 90 (42.25%)           | 120 (17.49%)       | 25 (8.83%)        | 1 (0.84%)                 | 31 (19.87%)              | 267 (18.33%)      |
| Other                 | 10 (4.69%)            | 42 (6.12%)         | 9 (3.18%)         | 2 (1.68%)                 | 5 (3.21%)                | 68 (4.67%)        |
| **Time since OI and HAART in weeks** | 7.4 (3–16.6) | 5.4 (3–10) | 4.4 (1.1–10.9) | 2.6 (0.7–4.9) | 5.3 (2.7–8.3) | 5.1 (2.3–10.1) |
| **Patients in early HAART group, n (%)** | 59 (27.7%) | 241 (3513%) | 136 (48.06%) | 81 (68.07%) | 63 (40.38%) | 580 (39.9%) |

MSM = Men who have sex with men; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; OI = opportunistic infection; Early HAART group = those who initiated HAART within 4 weeks after diagnosis of OI.

doi:10.1371/journal.pone.0153921.t001

### Table 2. Number of cases of each opportunistic infection reported according to site and combined.

| Disease                  | FH-Argentina n = 213 (%) | FC-Brazil n = 686 (%) | FA-Chile n = 283 (%) | IHSS/HE-Honduras n = 119 (%) | INCMSNZ-México n = 156 (%) | Combined n = 1457 (%) |
|--------------------------|--------------------------|-----------------------|----------------------|-----------------------------|---------------------------|----------------------|
| Tuberculosis             | 27 (12.7)                | 340 (49.6)            | 21 (7.4)             | 26 (21.8)                   | 40 (25.6)                 | 454 (31.2)           |
| Pneumocystis             | 53 (24.9)                | 124 (18.1)            | 125 (44.2)           | 10 (8.4)                    | 35 (22.4)                 | 347 (23.8)           |
| Invasive candidiasis     | 24 (11.3)                | 84 (12.2)             | 91 (32.2)            | 10 (8.4)                    | 27 (17.3)                 | 236 (16.2)           |
| Toxoplasmosis            | 20 (9.4)                 | 49 (7.1)              | 9 (3.2)              | 42 (35.3)                   | 6 (3.8)                   | 126 (8.6)            |
| Recurrent pneumonia      | 45 (21.1)                | 3 (0.4)               | 1 (0.4)              | 17 (14.3)                   | 0 (0.0)                   | 66 (4.5)             |
| Cryptococcal meningitis  | 16 (7.5)                 | 14 (2.0)              | 11 (3.9)             | 8 (6.7)                     | 2 (1.3)                   | 51 (3.5)             |
| Severe recurrent herpes  | 0 (0.0)                  | 21 (3.1)              | 8 (2.8)              | 0 (0.0)                     | 2 (1.3)                   | 31 (2.1)             |
| Cytomegalovirus (CMV)    | 2 (0.9)                  | 11 (1.6)              | 4 (1.4)              | 0 (0.0)                     | 10 (6.4)                  | 27 (1.9)             |
| Histoplasmosis           | 7 (3.3)                  | 6 (0.9)               | 0 (0.0)              | 6 (5.0)                     | 8 (5.1)                   | 27 (1.9)             |
| CMV retinitis            | 6 (2.8)                  | 10 (1.5)              | 2 (0.7)              | 0 (0.0)                     | 7 (4.5)                   | 25 (1.7)             |
| Cryptosporidosis         | 3 (1.4)                  | 5 (0.7)               | 3 (1.1)              | 0 (0.0)                     | 4 (2.6)                   | 15 (1.0)             |
| Atypical mycobacterium   | 3 (1.4)                  | 7 (1.0)               | 2 (0.7)              | 0 (0.0)                     | 2 (1.3)                   | 14 (1.0)             |
| Isosporiasis             | 2 (0.9)                  | 7 (1.0)               | 3 (1.1)              | 0 (0.0)                     | 1 (0.6)                   | 13 (0.9)             |
| Encephalopathy           | 4 (1.9)                  | 0 (0.0)               | 0 (0.0)              | 0 (0.0)                     | 8 (5.1)                   | 12 (0.8)             |
| Progressive multifocal leukoencephalopathy | 1 (0.5) | 5 (0.7) | 2 (0.7) | 0 (0.0) | 2 (1.3) | 10 (0.7) |
| Coccidioidomycosis       | 0 (0.0)                  | 0 (0.0)               | 1 (0.4)              | 0 (0.0)                     | 0 (0.0)                   | 1 (0.1)              |
| Salmonellosis            | 0 (0.0)                  | 0 (0.0)               | 0 (0.0)              | 0 (0.0)                     | 1 (0.6)                   | 1 (0.1)              |

doi:10.1371/journal.pone.0153921.t002
probability of starting HAART within 4 weeks of diagnosis with an OI as a function of calendar year, after controlling for the same variables. The results of all three panels are consistent and demonstrate a strong temporal trend towards earlier initiation of HAART after diagnosis of an OI (p \textless 0.01 for each analysis).

Factors associated with early HAART initiation

Factors associated with starting HAART within the first 4 weeks after OI diagnosis are shown in Table 3. In addition to more recent calendar year, a lower CD4 count at enrolment was associated with being more likely to start HAART early. Patients from the site in Honduras as compared to Brazil also had an increased probability of being early HAART initiators (p-value < 0.001). After controlling for other factors, patients diagnosed with TB were less likely to start HAART within 4 weeks than patients diagnosed with other OIs. Factors associated with early HAART initiation were similar when the time from OI to HAART initiation was kept as a continuous variable and analyzed with median regression (data not shown).

Discussion

The main purpose of this work was to describe the changes that have occurred over time in Latin America regarding the timing of HAART initiation after diagnosis of an opportunistic infection. We found that the time between OI diagnosis and starting HAART has decreased significantly in recent years, but that there is substantial heterogeneity between sites. After the year 2009 most international guidelines recommended HAART initiation as early as possible after an OI diagnosis [14]. In concordance with this recommendation we found a statistically
significant higher probability of early HAART initiation after 2009 than before. The practice did not change immediately in 2009, but rather was a gradual change, and appears to have been occurring prior to 2009, although it has perhaps accelerated in more recent years.

Because of potentially different clinical implications compared to other OIs, tuberculosis cases were analyzed separately but also included in the overall analysis. Patients diagnosed with tuberculosis, as opposed to other OIs, were more likely to delay HAART initiation. The evidence regarding the optimal time for starting HAART after a tuberculosis event has been clearly documented in several important clinical trials [9–11]. In each of these, the lower the CD4 count at TB diagnosis, the higher the benefit of starting HAART earlier. Even though TB-IRIS occurs more frequently with lower CD4 count when starting HAART, mortality is higher if treatment is deferred [9–11].

In a recent observational study conducted in Uganda in patients with HIV and tuberculosis co-infection and CD4 counts less than 50 cells/mm³, the proportion starting HAART within 14 and 30 days of diagnosis of tuberculosis increased from 7% to 14% and from 14% to 86%, respectively, over the period of observation [18]. The ICONA cohort in high-income countries from Europe recently found a significant increase in early HAART initiation after a documented OI in three different periods of time between 1996 and 2013 [19]. Factors associated with early initiation of HAART in this context were recent calendar year, lower CD4 count, and a recent HIV diagnosis, which is consistent with our results.
In contrast to the evidence existing for outcomes according to time to HAART initiation after occurrence of tuberculosis, the evidence through clinical trials for other OIs is scarce. The multisite ATCG 5164 study published by Zolopa and colleagues in 2009 demonstrated a statistically favorable composite outcome (proportion of individuals alive, free of AIDS and with undetectable viral load) at 48 weeks after enrolment in patients presenting with an OI (including cryptococcal meningitis, but excluding TB) in whom HAART was initiated in the first 2 weeks in comparison to those who initiated between 6 to 12 weeks, especially in more immunosuppressed patients with CD4 counts less than 50 cells/mm³ [7]. A more recent prospective study performed only in Spain (PISCIS cohort) evaluated the impact of timing of HAART on

| Table 3. Adjusted logistic model for factors associated with starting HAART within the first 4 weeks after opportunistic infection. |
|---------------------------------------------------------------|
| **Odds Ratio** | **(95% Confidence Interval)** | **p-value** |
| **Age (years)** | | | |
| 20 | 1.02 | 0.88 | 1.19 | 0.78 |
| 30 | 1.05 | 0.77 | 1.42 | 0.65 |
| 40 | 1.07 | 0.67 | 1.74 | 0.59 |
| 50 | 1.04 | 0.44 | 2.47 | 0.92 |
| **Male gender** | | | |
| 1 | 0.84 | 0.57 | 1.23 | 0.427 |
| **Route of transmission** | | | |
| Heterosexual | 1 | | |
| MSM | 0.84 | 0.57 | 1.23 | 0.427 |
| Other | 1.09 | 0.42 | 2.86 | 0.26 |
| Unknown | 1.49 | 0.83 | 2.64 | 0.26 |
| **CD4 count (cells/mm³)** | | | |
| 25 | 1 | | |
| 50 | 0.94 | 0.92 | 0.96 | <0.001 |
| 100 | 0.83 | 0.77 | 0.89 | 0.05 |
| 150 | 0.73 | 0.65 | 0.83 | 0.03 |
| 200 | 0.64 | 0.54 | 0.77 | 0.05 |
| **TB** | | | |
| 0.34 | 0.24 | 0.51 | 0.88 |
| **CM** | | | |
| 0.94 | 0.39 | 2.23 | 0.88 |
| **Year of OI** | | | |
| 2002 | 1 | | |
| 2004 | 1.06 | 0.83 | 1.36 | <0.001 |
| 2006 | 1.16 | 0.72 | 1.85 | 0.88 |
| 2008 | 1.42 | 0.83 | 2.44 | 0.33 |
| 2010 | 1.98 | 1.19 | 3.3 | 0.33 |
| 2012 | 2.83 | 1.63 | 4.9 | 0.33 |
| **Site** | | | |
| FC-Brazil | 1 | | |
| FH-Argentina | 0.69 | 0.38 | 1.26 | 0.25 |
| FA-Chile | 1.58 | 0.99 | 2.54 | 0.09 |
| IHSS/HE-Honduras | 4.48 | 2.32 | 8.65 | 0.001 |
| INCMNSZ- México | 0.72 | 0.46 | 1.14 | 0.001 |

MSM = Men who have sex with men; TB = tuberculosis; CM = cryptococcal meningitis; OI = opportunistic infection.

doi:10.1371/journal.pone.0153921.t003
disease progression and death among HIV-infected patients with an AIDS-defining event [8]. The results showed that deferring HAART was significantly associated with faster progression to a new AIDS-defining event or death overall [8].

The recently published START study results support the initiation of HAART regardless of CD4 count [20], and demonstrated the significant benefits for initiating at CD4 counts > 500 cells/mm³ versus deferring until CD4 counts fall below 350 cells/mm³ (which was the previous recommendation according to WHO guidelines published in 2010) [12,14]. In the context of an OI, international guidelines have recommended initiation of HAART as early as possible since 2009, except in certain circumstances such as cryptococcal meningitis [6,21], yet evaluation of the translation of this recommendation to routine care of patients is limited. In our study, trends over time for reducing the time from OI diagnosis to HAART initiation were clearly significant when all OIs were included. However, we found no distinct trend in earlier HAART initiation after diagnosis of cryptococcal meningitis, perhaps in part due to evolving knowledge about the optimal timing of HAART in this circumstance; the number of cryptococcal meningitis cases included in our study was low (n = 51) which may have limited our power to detect temporal trends.

The heterogeneity of the timeline to HAART initiation after an OI between sites included in our cohort may reflect different patterns of adopting “state of the art” practice in each country. The diverse nature of specific OIs across sites may have driven physicians to differentially defer HAART (for example, the Brazilian site contributed half of the TB events in the study) due perhaps to differing concerns for IRIS. In the context of TB/HIV co-infection, IRIS has been analyzed in several studies. The findings suggest that the benefits of starting HAART in patients with very advanced disease might supersede the risks of mortality attributed to IRIS itself [11,22]. In that sense, prevalence of IRIS may vary between our sites and contribute to the heterogeneity of the results. Moreover, limited availability of diagnostic tests and infrastructure at some sites may delay OI diagnosis and therefore timing of HAART initiation. Finally, barriers to the access of HAART in such situations may differ between HAART programs in each region. Therefore, evaluations to describe the adoption of these recommendations in a “real life” context are crucial to identify potential areas for improvement.

We recognize strengths and limitations for our study. To our knowledge this is the first study in Latin America to describe the temporal trends of the time from a first diagnosis of OI to the time of starting HAART in HIV-infected treatment-naïve adults. However, even though patients from several Latin American countries were included, the generalizability and external validity of our results in the region are limited. Our cohort does not collect data on IRIS, which could have further added to the analysis. Opportunistic infections were not uniformly collected across sites and there may have been some missed or incorrect diagnoses. Finally, analysis of the impact of the timing of HAART initiation on mortality was not performed and warrants further evaluation.

**Conclusion**

In this “real life” evaluation conducted in several sites in Latin America, the time from diagnosis of an OI to HAART initiation has decreased, coinciding with the publication of evidence of the benefits of early HAART initiation. In multivariable analyses there was a clear association of shorter time to HAART initiation in recent years of presentation. Other factors associated with early HAART initiation after an OI diagnosis were non-tuberculosis diagnosis and low CD4 counts at baseline. We found important heterogeneity between sites, which may reflect differences in clinical practices and resources, local guidelines, and access to HAART. The impact of the timing of HAART initiation after OI on patient survival in this “real life” context needs further evaluation.
Acknowledgments

We gratefully acknowledge all patients, caregivers, and data managers involved in the CCASAnet cohort. All principal investigators from the CCASAnet Cohort: Pedro Cahn, Beatriz Grinsztejn, Marcelo Wolff, Jean W. Pape, Daisy Machado, Jorge Pinto, Denis Padgett, Juan Sierra-Madero, Eduardo Gotuzzo.

Author Contributions

Conceived and designed the experiments: BCR JSM. Analyzed the data: YCV BES. Contributed reagents/materials/analysis tools: YCV BES BCR. Wrote the paper: BCR YCV BES BG MW CPC DP GC VF KJ AKP CM JSM.

References

1. Crabtree-Ramirez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Cortes C, et al. (2011) Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters. PLoS ONE 6: e20272. doi:10.1371/journal.pone.0020272 PMID: 21637802
2. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (London, England) 360: 119–129.
3. Hocking JS, Rodger AJ, Rhodes DG and Crofts N (2000) Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis—characteristics of individuals. Int J STD AIDS 11: 503–508. PMID: 10990334
4. Chadborn TR, Baster K, Delpech VC, Sabin CA, Sinka K, Rice BD, et al. (2005) No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993–2002). AIDS (London, England) 19: 513–520.
5. Chadborn TR, Delpech VC, Sabin CA, Sinka K and Evans BG (2006) The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004). AIDS (London, England) 20: 2371–2379.
6. Boullware DR, Meya DB, Muzoora C, Rolphes MA, Huppierr Hullsieck K, Musubire A, et al. (2014) Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. The New England journal of medicine 370: 2487–2498. doi:10.1056/NEJMoa1312884 PMID: 24963568
7. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. (2009) Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 4: e5575. doi:10.1371/journal.pone.0005575 PMID: 19440326
8. Manzardo C, Esteve A, Ortega N, Podzamczer D, Murillas J, Segura F, et al. (2013) Optimal timing for initiation of highly active antiretroviral therapy in treatment-naive human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. Clin Microbiol Infect 19: 646–653. doi:10.1111/j.1469-0691.2012.03991.x PMID: 22967234
9. Havlir DV, Kendall MA, Iwe P, Kumwenda J, Swindells S, Qasba SS, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. The New England journal of medicine 365: 1482–1491. doi:10.1056/NEJMoa1013607 PMID: 22010914
10. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerriniet E, et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. The New England journal of medicine 365: 1471–1481. doi:10.1056/NEJMoa1013911 PMID: 22010913
11. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. The New England journal of medicine 365: 1492–1501. doi:10.1056/NEJMoa11014181 PMID: 22010915
12. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. The New England journal of medicine 362: 697–706. doi:10.1056/NEJMoa0905848 PMID: 20181971
13. Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, et al. (2010) Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials 11: 248–259. doi:10.1310/hct1105-248 PMID: 21126955
14. WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach—2010 rev.
15. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, et al. (2007) Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the
International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 36: 969–976. PMID: 17846055

16. WHO (2007) WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children.

17. (1993) From the Centers for Disease Control and prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA: the journal of the American Medical Association 269: 460.

18. Vijayan T, Semitala FC, Matsiko N, Elyanu P, Namusobya J, Havlir DV, et al. (2013) Changes in the timing of antiretroviral therapy initiation in HIV-infected patients with tuberculosis in Uganda: a study of the diffusion of evidence into practice in the global response to HIV/AIDS. Clin Infect Dis 57: 1766–1772. doi: 10.1093/cid/cit654 PMID: 24065326

19. Cingolani A, Cozzi-Lepri A, Ammassari A, Mussini C, Ursitti MA, Caramello P, et al. (2014) Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort. PLoS ONE 9: e89861. doi:10.1371/journal.pone.0089861 PMID: 24587081

20. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. (2015) Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. The New England journal of medicine 373: 795–807. doi: 10.1056/NEJMoa1506816 PMID: 26192873

21. Bisson GP, Molefi M, Bellamy S, Thakur R, Steenhoff A, Tamuhla N, et al. (2013) Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis 56: 1165–1173. doi: 10.1093/cid/cit019 PMID: 23362285

22. Worodria W, Massinga-Loembe M, Mazakpwe D, Luzinda K, Menten J, Van Leth F, et al. (2011) Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999) 58: 32–37. doi: 10.1097/QAI.0b013e3182255dc2 PMID: 21654499